Search Result

Results for "

liver steatosis

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AMPK (1) AP-1 (1) Apoptosis (1) Aryl Hydrocarbon Receptor (3) Autophagy (1) Bcl-2 Family (1) Caspase (2) CDK (1) COX (1) Cyclin G-associated Kinase (GAK) (1) Cytochrome P450 (1) Endogenous Metabolite (3) ERK (1) Fatty Acid Synthase (FASN) (1) Ferroptosis (1) Fluorescent Dye (1) FXR (3) Glutathione S-transferase (1) HBV (1) HCV (1) HSP (1) Interleukin Related (1) JNK (2) MDM-2/p53 (1) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) mTOR (1) NF-κB (2) P-glycoprotein (1) p38 MAPK (1) Phosphatase (1) PPAR (1) Reactive Oxygen Species (1) Stearoyl-CoA Desaturase (SCD) (1) TGF-β Receptor (2) TNF Receptor (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (2) Infection (2) Inflammation/Immunology (10) Metabolic Disease (8)

By Targets:

AMPK (1)

AP-1 (1)

Apoptosis (1)

Aryl Hydrocarbon Receptor (3)

Autophagy (1)

Bcl-2 Family (1)

Caspase (2)

CDK (1)

COX (1)

Cyclin G-associated Kinase (GAK) (1)

Cytochrome P450 (1)

Endogenous Metabolite (3)

ERK (1)

Fatty Acid Synthase (FASN) (1)

Ferroptosis (1)

Fluorescent Dye (1)

FXR (3)

Glutathione S-transferase (1)

HBV (1)

HCV (1)

HSP (1)

Interleukin Related (1)

JNK (2)

MDM-2/p53 (1)

Microtubule/Tubulin (1)

Mitochondrial Metabolism (1)

mTOR (1)

NF-κB (2)

P-glycoprotein (1)

p38 MAPK (1)

Phosphatase (1)

PPAR (1)

Reactive Oxygen Species (1)

Stearoyl-CoA Desaturase (SCD) (1)

TGF-β Receptor (2)

TNF Receptor (1)

By Research Areas:

Cancer (3)

Cardiovascular Disease (2)

Infection (2)

Inflammation/Immunology (10)

Metabolic Disease (8)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: LXR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-151932

FXR agonist 3	FXR	Inflammation/Immunology
FXR agonist 3 is an anti-NASH agent, acting by activating FXR. FXR agonist 3 inhibits COL1A1, TGF-β1, α-SMA and TIMP1 expression with anti-fibrogenic activity. FXR agonist 3 significantly reduces liver steatosis and inflammation, improves liver fibrosis level .

HY-112812

SCD1 inhibitor-1	Stearoyl-CoA Desaturase (SCD)	Metabolic Disease
SCD1 inhibitor-1 (Compound 48) is an orally active and liver-selective inhibitor of stearoyl-CoA desaturase 1 (SCD1) with an IC₅₀ of 8.8 nM for recombinant human SCD1 enzyme. SCD1 inhibitor-1 can be used in the study of diseases such as diabetes, hepatic steatosis and obesity .

HY-D1168

Oil Red O 3 Publications Verification	Fluorescent Dye	Metabolic Disease
Oil Red O is a fat-soluble diazol dye, with a maximum absorption at 518 nm. Oil Red O stains neutral lipids and cholesteryl esters but not biological membranes. Oil Red O can be used for detecting and quantifying hepatic steatosis in mouse liver biopsies. Oil Red O staining efficiently helps to visualize the radical changes that occur in tissues as metabolic disease occurs and progresses .

HY-104026CS

L-Kynurenine-13C10 sulfate hemihydrate	Aryl Hydrocarbon Receptor Endogenous Metabolite	Inflammation/Immunology
L-Kynurenine- ¹³C10 (sulfate hemihydrate) is the ¹³C labeled L-Kynurenine sulfate. L-Kynurenine sulfate hemihydrate, an aryl hydrocarbon receptor (AHR) agonist that activates AHR-directed, naive T cell polarization to the anti-inflammatory Treg phenotype .

HY-161926

YGT-31	PPAR	Metabolic Disease
YGT-31 is a modulator for PPARγ with an IC₅₀ of 1.72 μM, and a K_i of 0.62 μM. YGT-31 reduces blood glucose levels and improves insulin resistance in db/db mice type 2 diabetes models, through inhibition of CDK5-mediated PPARγ-Ser273 phosphorylation. YGT-31 exhibits anti-hepatic steatosis effect in mice non-alcoholic fatty liver disease (NAFLD) model .

HY-16521

VX-166	Caspase	Inflammation/Immunology
VX-166, a pan caspase inhibitor, can be used for the research of Non- Alcoholic Fatty Liver Disease (NAFLD), nonalcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), and other diseases involving fibrosis, steatosis, or inflammation of the liver .

HY-N2953

Borapetoside E	Fatty Acid Synthase (FASN)	Metabolic Disease
Borapetoside E can be isolated from T. crispa. Borapetoside E improves hyperglycemia, insulin resistance, hepatic steatosis, hyperlipidemia, and oxygen consumption in obese mice. Borapetoside E also inhibits SREBPs expression in the liver and adipose tissue .

HY-104026B

L-Kynurenine sulfate	Endogenous Metabolite Aryl Hydrocarbon Receptor	Inflammation/Immunology
L-Kynurenine sulfate, an aryl hydrocarbon receptor (AHR) agonist that activates AHR-directed, naive T cell polarization to the anti-inflammatory Treg phenotype .

HY-151959

FXR agonist 4	FXR	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
FXR agonist 4 (compound 10a) is an agonist of farnesoid X receptor (FXR) with an EC₅₀ value of 1.05 μM. FXR agonist 4 effectively improves hyperlipidemia, hepatic steatosis, insulin resistance and hepatic inflammation in DIO mice. FXR agonist 4 can be used for the research of non-alcoholic fatty liver disease (NAFLD) .

HY-104026BS

L-Kynurenine-13C10 sulfate	Aryl Hydrocarbon Receptor Endogenous Metabolite	Inflammation/Immunology
L-Kynurenine-13C10 (sulfate) is the 13C labeled L-Kynurenine sulfate. L-Kynurenine sulfate, an aryl hydrocarbon receptor (AHR) agonist that activates AHR-directed, naive T cell polarization to the anti-inflammatory Treg phenotype .

HY-130437

p-nitro-Pifithrin-α	MDM-2/p53 TGF-β Receptor Caspase	Infection Metabolic Disease
p-nitro-Pifithrin-α, a cell-permeable analog of pifithrin-α, is a potent p53 inhibitor. p-nitro-Pifithrin-α suppresses p53-mediated TGF-β1 expression in HK-2 cells. p-nitro-Pifithrin-α inhibits the activation of caspase-3 by Zika virus (ZIKV) strains. p-nitro-Pifithrin-α attenuates steatosis and liver injury in mice fed a high-fat diet [4]. non-alcoholic fatty liver disease .

HY-123986

CTPI-2 5+ Cited Publications	Mitochondrial Metabolism	Inflammation/Immunology Cancer
CTPI-2 is a third-generation mitochondrial citrate carrier SLC25A1 inhibitor with a K_D of 3.5 μM. CTPI-2 inhibits glycolysis, PPARγ, and its downstream target the glucose transporter GLUT4. CTPI-2 halts salient alterations of NASH reverting steatosis, preventing the evolution to steatohepatitis, reducing inflammatory macrophage infiltration in the liver and adipose tissue, and starkly mitigating obesity induced by a high-fat diet. Antitumor activity .

HY-B0766

Bicyclol SY801	Autophagy Apoptosis HBV HCV HSP Reactive Oxygen Species Bcl-2 Family Glutathione S-transferase p38 MAPK NF-κB Microtubule/Tubulin ERK JNK TNF Receptor Interleukin Related CDK Cyclin G-associated Kinase (GAK) mTOR P-glycoprotein Ferroptosis	Infection Inflammation/Immunology Cancer
Bicyclol (SY801) is an orally active derivative of the traditional Chinese medicine Schisandra chinensis, which has antiviral, anti-inflammatory, immunomodulatory, antioxidant, anti-steatosis, anti-fibrotic and anti-tumor activities. Bicyclol regulates the expression of heat shock proteins and plays an anti-apoptosis role in hepatocytes. Bicyclol reduces the activation of NF-κB and the levels of inflammatory factors in hepatocytes infected with hepatitis C virus (HCV) by inhibiting the activation of the ROS-MAPK-NF-κB pathway, and prevents ferroptosis in acute liver injury. Bicyclol can change the expression of Mdr-1, GSH/GST and Bcl-2, increase the intracellular concentration of anticancer drugs, and sensitize drug-resistant cells to anticancer drugs. Bicyclol inhibits the proliferation of human malignant hepatoma cells by regulating the PI3K/AKT pathway and the Ras/Raf/MEK/ERK pathway. Bicyclol can be used in the study of chronic hepatitis, acute liver injury, nonalcoholic fatty liver disease, liver fibrosis and hepatocellular carcinoma .

HY-122591

PTUPB 1 Publications Verification	COX	Metabolic Disease Cancer
PTUPB is a potent and dual sEH and COX-2 enzymes inhibitor with IC₅₀ of 0.9 nM and 1.26 μM, respectively .

HY-141645

IMM-H007 WS070117	AMPK TGF-β Receptor NF-κB JNK AP-1	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
IMM-H007 (WS070117) is an orally active and potent AMPK (AMP-activated protein kinase) activator and TGFβ1 (transforming growth factor β1) antagonist. IMM-H007 has protective effects in cardiovascular diseases via activation of AMPK. IMM-H007 negatively regulates endothelium inflammation through inactivating NF-κB and JNK/AP1 signaling. IMM-H007 inhibits ABCA1 degradation. IMM-H007 resolves hepatic steatosis in HFD-fed hamsters by the regulation of lipid metabolism. IMM-H007 can be used for the research of nonalcoholic fatty liver disease (NAFLD) and inflammatory atherosclerosis .

HY-134988

EDP-305	FXR Phosphatase Cytochrome P450	Inflammation/Immunology
EDP-305 is an orally active, potent and selective farnesoid X receptor (FXR) agonist, with EC₅₀ values of 34 nM (chimeric FXR in CHO cells) and 8 nM (full-length FXR in HEK cells). EDP-305 shows a potent and consistent antifibrotic effect. EDP-305 can be used for primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH) research .

Cat. No.	Product Name

HY-L199

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library	3,150 compounds
Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and is the primary liver manifestation of metabolic syndrome. The growth of NAFLD has coincided with the obesity epidemic. NAFLD is composed of excess lipid accumulation in the liver, causing steatotoxicity, and shows a wide range of histopathological abnormalities. NAFLD may progress from simple steatosis to Non-alcoholic steatohepatitis (NASH) with or without fibrosis (NASH), and eventually to cirrhosis and hepatocellular carcinoma. To date, very few drugs have been approved for marketing specifically for the treatment of NAFLD, so increased efforts to develop NAFLD drugs are necessary. MCE designs a unique collection of 3,150 small molecules with definite or potential anti-NAFLD activity, which is an important tool for studying the pathological mechanism of NAFLD and developing drugs for NAFLD.

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

3,150 compounds

Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and is the primary liver manifestation of metabolic syndrome. The growth of NAFLD has coincided with the obesity epidemic. NAFLD is composed of excess lipid accumulation in the liver, causing steatotoxicity, and shows a wide range of histopathological abnormalities. NAFLD may progress from simple steatosis to Non-alcoholic steatohepatitis (NASH) with or without fibrosis (NASH), and eventually to cirrhosis and hepatocellular carcinoma. To date, very few drugs have been approved for marketing specifically for the treatment of NAFLD, so increased efforts to develop NAFLD drugs are necessary.

MCE designs a unique collection of 3,150 small molecules with definite or potential anti-NAFLD activity, which is an important tool for studying the pathological mechanism of NAFLD and developing drugs for NAFLD.

Cat. No.	Product Name	Type